NCT02127359View on ClinicalTrials.gov

Whole-Exome Sequencing (WES) of Cancer Patients

CompletedOBSERVATIONAL
Enrollment

244

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2017

Study Completion Date

December 31, 2019

Conditions
Lung AdenocarcinomaColon Adenocarcinoma
Trial Locations (2)

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Insitute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT02127359 - Whole-Exome Sequencing (WES) of Cancer Patients | Biotech Hunter | Biotech Hunter